Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Where did you get the $232 billion from! Thin air?
Almost all buys but price flat
Last Trading Update
Revenue recognised for 2024 is expected to treble compared to 2023 with the growth of distributor sales, and with the planned launches of the Portrait PD-L1 test (services), see separate announcement today, the Portrait+ antibody staining kit (products), and the Parsortix BiDetectTM DNA solutions combining ctDNA and CTC-DNA analysis (products and services) all contributing to the Company's sales growth ambitions.
Business update - Streamlining services business extends cash runway
With the expected growth in molecular solutions requiring investment and considering ongoing adverse market conditions, we have made the decision to streamline our Services operations by closing the US clinical laboratory and focusing on a single UK-based centre of excellence. We have developed solutions for sample stability so that the physical location of the laboratory does not limit its capability to service customers across different geographies. The streamlining will enable us to focus our investment in multiple molecular platforms for different applications in a single location without duplicating these significant costs.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The build-up of revenues has been slower than hoped but is moving in the right direction and the Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."
Berenberg Bank reaffirmed their buy rating on shares of ANGLE (LON:AGL – Free Report) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 70 ($0.86) target price on the stock
There is a seller and they have been offloading in batches of 50000 and 25000. We will soon find out.
European Patent Office has granted a European Patent for its innovative CellKeep™ slide. A formal communication has also been received from the United States Patent and Trademark Office indicating that grant of the equivalent US patent application is imminent. News due soon
Bobat123
"There is also a distressed seller offloading for the past few days . Hopefully should be TR1 soon. That is what is also holding this back".
Do you have a crystal ball, or do you look at the tea leaves? Total guess based on Jack. In other words complete rubbish.
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
There is also a distressed seller offloading for the past few days . Hopefully should be TR1 soon. That is what is also holding this back
Im in. This looks like it could do a great run after yesterdays news
Since the RNS there has been 480K buy and also other big buys. Mms have been filling order.
Runway looks much clearer now.
Https://www.lse.co.uk/ShareBrokerTips.html?shareprice=AGL&share=Angle
Broker Rating 70p
Welcome. Astrazeneca is a global giant and the largest company on the FTSE 100. We're going to do well.
I've added as I see far more potential this year than 35p.
Also I got the feeling the chief has more to announce.
Hi Earl as per the interview many more deals are coming and there's a lot in the pipeline. Patience needed.
PD101
What interview; can you advise please?
Definitely not an insult, CEO says he expects potentially hundreds of millions worth of deals with AZ. Could see further announcements next week.
It's stupidly cheap at these prices and cashed up to Q2 2025 to boot. Imagine the mega deals that will land between now and then!
GLA